58%
Radiopharmaceuticals command this premium over small molecules
The theranostic revolution has made radiopharmaceuticals one of the most valuable modalities in biopharma licensing. With built-in companion diagnostics and precision targeting, these assets command significantly higher deal terms than traditional small molecules across all development stages.
Based on analysis of 600+ biopharma licensing deals from 2020-2026
Get deal intelligence in your inbox
Weekly benchmarks, market signals, and deal analysis from 1,900+ transactions.
No spam. Unsubscribe anytime.
Benchmarks powered by 1,900+ real biopharma licensing deals
Try the Deal Calculator →